BioSpace News Archive

Leidos, a FORTUNE® 500 science and technology leader, announced the formation of a Scientific Advisory Board for its Explorations in Global Health division within the Leidos Health Group.

Early data trends from first patient dosed in the AVR-RD-04 investigational gene therapy program for cystinosis show improvements across multiple measures

Schrödinger, Inc. announced the closing of its initial public offering of 13,664,704 shares of common stock at a public offering price of $17.00 per share, which includes 1,782,352 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds of approximately $232.3 million, before underwriting discounts and commissions and offering expenses payable by the Company.

Acura Pharmaceuticals, Inc. announced financial results for the three and six months ended June 30, 2019.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock.

Aethlon Medical, Inc., a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, reported financial results for its third quarter ended December 31, 2019 and provided an update on recent developments.

Universal Health Services, Inc. announced that it will report results for its fourth quarter and full year ended December 31, 2019 after the market closes on Wednesday, February 26, 2020.

Repro Med Systems, Inc. dba KORU Medical Systems announced that Don Pettigrew, President & CEO, will ring the Nasdaq Closing Bell on Wednesday, February 12, 2020 at 4:00 pm ET.

Cortexyme, Inc., a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, announced that it has closed its private placement offering.

Catalent, Inc. announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.